Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine

F. Fernandez, J. K. Levy, H. R. Samley, F. J. Pirozzolo, D. Lachar, J. Crowley, S. Adams, B. Ross, P. Ruiz

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

This report is a randomized, double-blind, comparative trial of desipramine with the psychomotor stimulant methylphenidate. Twenty HIV antibody-positive patients with depressive symptoms were randomly assigned to either drug. After individual dose titration, the mean daily dose of desipramine was 150 mg. and methylphenidate 30 mg. daily. The differences in responses between desipramine and methylphenidate were not statistically significant on various measures of depression. The antidepressant effect of methylphenidate did not occur any faster than that of desipramine. Both significantly reduced depressive and anxious symptomatology over the blinded portion of the treatments. Thus, methylphenidate relieves depressive symptomatology with efficacy similar to that of desipramine, offering an alternative to patients who are unable to tolerate standard tricyclic antidepressant therapy. The dopaminergic effects of methylphenidate are likely to mediate its antidepressant effects.

Original languageEnglish
Pages (from-to)53-67
Number of pages15
JournalInternational Journal of Psychiatry in Medicine
Volume25
Issue number1
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Methylphenidate
Desipramine
HIV
Depression
Antidepressive Agents
HIV Antibodies
Dopamine Agents
Tricyclic Antidepressive Agents
Therapeutics
Pharmaceutical Preparations

Keywords

  • AIDS
  • antidepressants
  • anxiety
  • cognition
  • comparison study
  • depression
  • desipramine
  • HIV infection
  • methylphenidate
  • PGL/ARC

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Fernandez, F., Levy, J. K., Samley, H. R., Pirozzolo, F. J., Lachar, D., Crowley, J., ... Ruiz, P. (1995). Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. International Journal of Psychiatry in Medicine, 25(1), 53-67.

Effects of methylphenidate in HIV-related depression : A comparative trial with desipramine. / Fernandez, F.; Levy, J. K.; Samley, H. R.; Pirozzolo, F. J.; Lachar, D.; Crowley, J.; Adams, S.; Ross, B.; Ruiz, P.

In: International Journal of Psychiatry in Medicine, Vol. 25, No. 1, 01.01.1995, p. 53-67.

Research output: Contribution to journalArticle

Fernandez, F, Levy, JK, Samley, HR, Pirozzolo, FJ, Lachar, D, Crowley, J, Adams, S, Ross, B & Ruiz, P 1995, 'Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine', International Journal of Psychiatry in Medicine, vol. 25, no. 1, pp. 53-67.
Fernandez F, Levy JK, Samley HR, Pirozzolo FJ, Lachar D, Crowley J et al. Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. International Journal of Psychiatry in Medicine. 1995 Jan 1;25(1):53-67.
Fernandez, F. ; Levy, J. K. ; Samley, H. R. ; Pirozzolo, F. J. ; Lachar, D. ; Crowley, J. ; Adams, S. ; Ross, B. ; Ruiz, P. / Effects of methylphenidate in HIV-related depression : A comparative trial with desipramine. In: International Journal of Psychiatry in Medicine. 1995 ; Vol. 25, No. 1. pp. 53-67.
@article{d9e1beb83ee94984b7de608f82635b01,
title = "Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine",
abstract = "This report is a randomized, double-blind, comparative trial of desipramine with the psychomotor stimulant methylphenidate. Twenty HIV antibody-positive patients with depressive symptoms were randomly assigned to either drug. After individual dose titration, the mean daily dose of desipramine was 150 mg. and methylphenidate 30 mg. daily. The differences in responses between desipramine and methylphenidate were not statistically significant on various measures of depression. The antidepressant effect of methylphenidate did not occur any faster than that of desipramine. Both significantly reduced depressive and anxious symptomatology over the blinded portion of the treatments. Thus, methylphenidate relieves depressive symptomatology with efficacy similar to that of desipramine, offering an alternative to patients who are unable to tolerate standard tricyclic antidepressant therapy. The dopaminergic effects of methylphenidate are likely to mediate its antidepressant effects.",
keywords = "AIDS, antidepressants, anxiety, cognition, comparison study, depression, desipramine, HIV infection, methylphenidate, PGL/ARC",
author = "F. Fernandez and Levy, {J. K.} and Samley, {H. R.} and Pirozzolo, {F. J.} and D. Lachar and J. Crowley and S. Adams and B. Ross and P. Ruiz",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "25",
pages = "53--67",
journal = "International Journal of Psychiatry in Medicine",
issn = "0091-2174",
publisher = "Baywood Publishing Co. Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of methylphenidate in HIV-related depression

T2 - A comparative trial with desipramine

AU - Fernandez, F.

AU - Levy, J. K.

AU - Samley, H. R.

AU - Pirozzolo, F. J.

AU - Lachar, D.

AU - Crowley, J.

AU - Adams, S.

AU - Ross, B.

AU - Ruiz, P.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - This report is a randomized, double-blind, comparative trial of desipramine with the psychomotor stimulant methylphenidate. Twenty HIV antibody-positive patients with depressive symptoms were randomly assigned to either drug. After individual dose titration, the mean daily dose of desipramine was 150 mg. and methylphenidate 30 mg. daily. The differences in responses between desipramine and methylphenidate were not statistically significant on various measures of depression. The antidepressant effect of methylphenidate did not occur any faster than that of desipramine. Both significantly reduced depressive and anxious symptomatology over the blinded portion of the treatments. Thus, methylphenidate relieves depressive symptomatology with efficacy similar to that of desipramine, offering an alternative to patients who are unable to tolerate standard tricyclic antidepressant therapy. The dopaminergic effects of methylphenidate are likely to mediate its antidepressant effects.

AB - This report is a randomized, double-blind, comparative trial of desipramine with the psychomotor stimulant methylphenidate. Twenty HIV antibody-positive patients with depressive symptoms were randomly assigned to either drug. After individual dose titration, the mean daily dose of desipramine was 150 mg. and methylphenidate 30 mg. daily. The differences in responses between desipramine and methylphenidate were not statistically significant on various measures of depression. The antidepressant effect of methylphenidate did not occur any faster than that of desipramine. Both significantly reduced depressive and anxious symptomatology over the blinded portion of the treatments. Thus, methylphenidate relieves depressive symptomatology with efficacy similar to that of desipramine, offering an alternative to patients who are unable to tolerate standard tricyclic antidepressant therapy. The dopaminergic effects of methylphenidate are likely to mediate its antidepressant effects.

KW - AIDS

KW - antidepressants

KW - anxiety

KW - cognition

KW - comparison study

KW - depression

KW - desipramine

KW - HIV infection

KW - methylphenidate

KW - PGL/ARC

UR - http://www.scopus.com/inward/record.url?scp=0029047853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029047853&partnerID=8YFLogxK

M3 - Article

C2 - 7649718

AN - SCOPUS:0029047853

VL - 25

SP - 53

EP - 67

JO - International Journal of Psychiatry in Medicine

JF - International Journal of Psychiatry in Medicine

SN - 0091-2174

IS - 1

ER -